Platelet-derived CXC chemokines: Old players in new games

Immunological Reviews

Volumn 177, Issue , 2000, Pages 204-216

  Brandt, E ^a   Ludwig, A ^a   Petersen, F ^a   Flad, H D ^a  

^a RESEARCH CENTER BORSTEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA THROMBOGLOBULIN; CHEMOKINE; CHEMOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR; THROMBOCYTE FACTOR 4;

HOST RESISTANCE; HUMAN; LEUKOCYTE ACTIVATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DEGRADATION; REGULATORY MECHANISM; REVIEW; TISSUE REPAIR;

EID: 0033652243     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2000.17705.x     Document Type: Review

References (81)

1. Chemokines
2. Recent advances in chemokines and chemokine receptors
3. Human platelet factor 4: Purification and characterization by affinity chromatography. Purification of human platelet factor 4
4. The isolation and characterisation of a platelet-specific β-globulin (β-thromboglobulin) and the detection of antiurokinase and antiplasmin released from thrombin-aggregated washed human platelets
5. Amino acid sequence of human platelet factor 4
6. Complete covalent structure of human β-thromboglobulin
7. Cloning and characterization of platelet factor 4 cDNA derived from a human erythroleukemic cell line
8. Cloning of cDNA coding for connective tissue activating peptide III from a human platelet-derived lambda gt 11 expression library
9. Biologic and biochemic properties of recombinant platelet factor 4 demonstrate identity with the native protein
10. Inhibition of angiogenesis by recombinant human platelet factor 4 and related peptides
11. Purification, crystallization and preliminary X-ray diffraction analysis of recombinant neutrophil-activating peptide 2 (rhNaP-2)
12. Structure and bioactivity of recombinant human CTAP-III and NAP-2
13. New synthesis of a platelet-specific protein: Platelet factor 4 synthesis in megakaryocyte-enriched rabbit bone-marrow culture system
14. Occurrence of platelet basic protein, a precursor of low affinity platelet factor 4 and β-thromboglobulin, in human platelets and megakaryocytes
15. The immunoelectron microscopic localization of human platelet factor 4 in tissue mast cells
16. Leukocyte-derived growth factor links the PDGF and CXC chemokine families of peptides
17. Genes for β-thromboglobulin and platelet factor 4 are closely linked and form part of a cluster of related genes on chromosome 4
18. Crystal structure of recombinant human platelet factor 4
19. 1H-nuclear magnetic resonance spectroscopy
20. 2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities
21. Structural requirements of platelet chemokines for neutrophil activation
22. Chemokine receptor specific for IP 10 and MIG: Structure, function, and expression in activated T-lymphocytes
23. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg
24. Structural requirements for interleukin-8 function identified by design of analogs and CXC chemokine hybrids
25. Effects of the neutrophil-activating peptide NAP-2, platelet basic protein, connective tissue-activating peptide III, and platelet factor 4 on human neutrophils
26. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2
27. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects
28. The amino-terminal residues in the crystal structure of connective tissue activating peptide III (des 10) block the ELR chemotactic sequence
29. A novel cleavage product of β-thromboglobulin formed in cultures of stimulated mononuclear cells activates neutrophils
30. Characterization of a platelet-derived factor modulating phagocyte functions and cooperating with interleukin 1
31. Are platelet factor 4 and β-thromboglobulin markers of cardiovascular disorders?
32. Plasma levels of β-thromboglobulin and platelet factor 4 as indices of platelet activation in vivo
33. Interaction of platelet factor four with cultured vascular endothelial cells
34. The release, distribution, and clearance of human β-thromboglobulin and platelet factor 4
35. The purification and mechanism of action of human antithrombin-heparin cofactor
36. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
37. 2 production and binds to a specific site in bovine aortic endothelial cells
38. Negative regulation of human megakaryocytopoiesis by human platelet factor 4 (PF-4) and connective tissue-activating peptide III (CTAP-III)
39. Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor
40. Connective tissue activation XXXIV: Effects of proteolytic processing on the biologic activities of CTAP-III
41. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides
42. 165 using several concurrent mechanisms
43. Inhibition of in vitro angiogenesis by platelet factor-4-derived peptides and mechanism of action
44. The IP-10 chemokine binds to a specific cell surface heparan sulfate shared with platelet factor 4 and inhibits endothelial cell proliferation
45. Interleukin-8 as a macrophage-derived mediator of angiogenesis
46. Chemotactic activity of platelet α granule proteins for fibroblasts
47. Platelet factor 4 is chemotactic for neutrophils and monocytes
48. In vitro effects of platelet factor 4 on normal human neutrophil functions
49. Chemotactic activity and receptor binding of neutrophil attractant/activation protein-1 (NAP-1) and structurally related host defense cytokines: Interaction of NAP-2 with the NAP-1 receptor
50. TNF-α renders human neutrophils responsive to platelet factor 4
51. The CXC-chemokine neutrophil-activating peptide-2 induces two distinct optima of neutrophil chemotaxis by differential interaction with interleukin-8 receptors CXCR-1 and CXCR-2
52. Platelet factor 4-induced neutrophil-endothelial cell interaction: Involvement of mechanisms and functional consequences different from those elicited by interleukin-8
53. 2-terminally processed forms
54. Recombinant tumor necrosis factor-α potentiates neutrophil degranulation in response to host defense cytokines neutrophil-activating peptide 2 amd IL-8 by modulating cyclic AMP levels
55. Differential effects of neutrophil-activating peptide 1/IL-8 and its homologues on leukocyte adhesion and phagocytosis
56. Characterization of a platelet derived factor modulating phagocyte functions and cooperating with interleukin 1
57. + CXC-chemokine platelet basic protein PBP
58. Properties of monocyte chemotactic and activating factor (MCAF) purified from a human fibrosarcoma cell line
59. Comparison of biological responses of human monocytes and THP- 1 cells to chemokines of the intercrine-β family
60. The CXC-chemokine platelet factor 4 promotes monocyte survival and induces monocyte differentiation into macrophages
61. Identification and characterization of specific receptors for interleukin-8 from the surface of human monocytes
62. 2+](i) changes and respiratory burst in human neutrophils and monocytes induced by NAP-1/interleukin-8, and gro/MGSA
63. Induction of functional IL-8 receptors by IL-4 and IL-13 in human monocytes
64. A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4
65. Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and β-thromboglobulin
66. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases
67. Neutrophils can generate their activator neutrophil-activating peptide 2 by proteolytic cleavage of platelet-derived connective tissue-activating peptide III
68. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets
69. A novel molecular variant of the neutrophil-activating peptide 2 NAP-2 with enhanced biological activity is truncated at the C-terminus: Identification by antibodies with defined epitope specificity
70. Limited and denned truncation at the C-terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2)
71. Novel C-terminally truncated isoforms of the CXC-chemokine β-thromboglobulin and their impact on neutrophil functions
72. The crystal structure of recombinant human neutrophil-activating peptide-2. (M6L) at 1.9-Å resolution
73. A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation
74. Characterization of a neutrophil cell surface glycosaminoglycan that mediates binding of platelet factor 4
75. 1H NMR spectroscopy
76. Molten globule monomer to condensed dimer: Role of disulfide bonds in platelet factor-4 and subunit association
77. 1H NMR spectroscopy and circular dichroism
78. Neutrophil-activating peptide-2 and melanoma growth-stimulatory activity are functional as monomers for neutrophil activation
79. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils
80. In vivo, in vitro, and molecular aspects of interleukin-8 and the interleukin-8 receptors
81. Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC-chemokines